Vallabh Janardhan: Vascular Disease Is Ultimately A Story of Thrombosis
Vallabh Janardhan, Co-Founder and CMO at Insera Therapeutics, Inc., shared on LinkedIn:
”Dallas CV Updates 2026 reinforced something I’ve been thinking about increasingly: vascular disease is ultimately a story of thrombosis.
From coronary plaque rupture to embolic stroke to venous thromboembolism, the final common pathway is clot biology.
A particularly compelling discussion this year centered on Lipoprotein(a) by Dr. Shahzeb Khan — not only as an atherogenic particle, but as a pro-thrombotic contributor that may amplify clot formation across vascular beds.
As our understanding deepens, prevention and intervention are no longer separate conversations.
Credit to Dr. Srini Potluri and Dr. Robert Smith for convening a forum that blends clinical excellence with forward-looking discussion at Baylor Scott and White The Heart Hospital.
Always energizing to engage with colleagues shaping the next phase of cardiovascular care in Dallas and beyond.”
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 01:13Francesc Formiga: Updated Evidence on LAA Closure Versus Oral Anticoagulation in AF
-
Oct 4, 2026, 01:11Alicja Urbaniak: Targeting CD148 to Develop New Antithrombotic Therapies
-
Oct 4, 2026, 01:03Susan Mou: Presenting Long-Term Clinical Outcomes in SCD and TDT
-
Oct 4, 2026, 01:00Mark Johnson: Elevating Patient and Warrior Voices During Sickle Cell Awareness Month
-
Oct 4, 2026, 00:55Pier Maria Fornasari: Possible New Target for SCD and Beta Thalassemia Treatment
-
Oct 4, 2026, 00:48Sthanu Subramanian: Mechanisms, Clinical Phenotypes, Imaging, and Treatment of CVT
-
Oct 4, 2026, 00:33Ashish Pemawat: Can We Protect the Brain while We Restore Blood Flow?
-
Oct 4, 2026, 00:32Marta Nowakowska-Kotas: Could a Small Rise in Creatinine after Thrombectomy in Stroke Patients Be an Early Warning Sign?
-
Oct 4, 2026, 00:26Mohammad Nafeli Shahrestani: CXCL10 Associated With Increased Long-Term Risk of Ischemic Stroke